Research programme: Natural killer cell-based therapeutics - BeOne Medicines
Latest Information Update: 28 Jul 2025
At a glance
- Originator BeiGene
- Developer BeOne Medicines; Shoreline Biosciences
- Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Unspecified
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for research development in Cancer in China (Parenteral)
- 28 Jul 2025 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 28 Jul 2025 No recent reports of development identified for research development in Unspecified in China (Parenteral)